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esponsibility of InstAbstract UDP-glucuronosyltransferase 1A9 (UGT1A9) is a major phase II enzyme responsible for elimination
of drugs and endogenous molecules. Clinical data have shown increased elimination of UGT1A9 substrates in
pregnant women or oral contraceptive users, but the role of estrogen in the regulation of UGT1A9 expression
remains unknown. In this study, we investigated the effect of 17β-estradiol (E2) on UGT1A9 expression and the
role of ERα in the transcriptional regulation of UGT1A9. E2 signiﬁcantly increased UGT1A9 promoter activity
in HepG2 cells in the presence of ERα. UGT1A9 induction by E2 was abrogated by antiestrogen ICI182,780 in
HepG2 cells that constitutively express ERα. Results from transient transfection of ERαmutants into HepG2 cells
demonstrated that mutation at DNA-binding domain of ERα abrogates increased UGT1A9 promoter activity by
E2. Deletion and mutation assays of UGT1A9 promoter revealed a putative ERE located within 2262/1987
region. Examination of healthy human liver tissues revealed signiﬁcantly higher UGT1A9 expression in women
as compared to men. Together, these ﬁndings provide a mechanistic basis for the previous clinical reports and
may shed a light on identifying sources for inter-individual variability in UGT1A9-mediated drug metabolism.
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UGT1A9 induction by E2 5051. Introduction
UDP-glucuronosyltransferases (UGTs) are major phase II enzymes
and catalyze conjugation of glucuronic acid to substrates, which is an
important metabolic and detoxiﬁcation pathway for drugs and
endogenous compounds1. Drug-metabolizing UGTs in humans are
largely divided into two families, i.e., UGT1A (UGT1A1, 1A3, 1A4,
1A5, 1A6, 1A7, 1A8, 1A9, and 1A10) and UGT2B (UGT2B4, 2B7,
2B10, 2B11, 2B15, 2B17, and 2B28)2. Among these, UGT1A9 is
one of major UGT isoforms expressed in the liver (6% of hepatic
UGT expression)3. UGT1A9 is responsible for the glucuronidation of
multiple endogenous molecules (e.g., thyroid hormones) and drugs (e.
g., propofol and acetaminophen)4–6.
Clinical data suggest that estrogen may enhance UGT1A9
expression and/or activity. For example, the area under the curve
(AUC) ratios of the glucuronide metabolites to propofol were higher
in women (1.3- to 2.9-fold) than in men7. Users of oral contraceptives
exhibited signiﬁcantly higher systemic clearances of acetaminophen
than non-users8. Also, pregnant women showed 1.5-fold higher
systemic clearances of acetaminophen as compared to nonpregnant
controls8, and this has been attributed to increased glucuronidation of
acetaminophen in pregnant women9. These results suggest potential
upregulation of UGT1A9 by estrogen; however, whether and how
estrogen modulates UGT1A9 expression remains unknown.
17β-Estradiol (E2) is a primary female sex hormone and a key
regulator of growth and differentiation in many tissues including
female reproductive tissues, mammary tissues and cardiovascular
systems10. The biological action of E2 is mediated by estrogen
receptors (ER), and ERα is the major subtype expressed in the
liver10,11. Upon activation by E2, ER binds to estrogen response
element (ERE) in the promoter region of target genes for transcriptional
regulation of the genes. E2 has been reported to regulate expression of
multiple drug-metabolizing enzyme genes including cytochrome P450
(CYP) 2B6, sulfotransferase 2A1, and UGT1A410,12,13. In this study,
we investigated the effect of E2 on UGT1A9 expression and the role
of ERα in the transcriptional regulation of UGT1A9. Our results show
that estrogen upregulates UGT1A9 expression, and this potentially
underlies the reported pharmacokinetic sex differences in UGT1A9-
mediated drug metabolism.2. Materials and methods
2.1. Chemicals and reagents
E2 and ICI182,780 were purchased from Sigma–Aldrich (St.
Louis, MO, USA).
2.2. Cell cultures
HepG2, HEK293T (American Type Culture Collection, Manassas,
VA, USA), and HepG2-ER cells (HepG2 cells stably expressing ERα
kindly provided by Dr. David Shapiro, University of Illinois at
Urbana-Champaign, USA) were cultured in complete Dulbecco's
modiﬁed Eagle's medium supplemented with 10% fetal bovine serum,
2 mmol/L L-glutamine, 100 U penicillin/mL, 100 μg streptomycin/mL,
and 1% minimum Eagle's medium nonessential amino acids.
2.3. Plasmids
Upstream regulatory region (2262/þ24) of UGT1A9 was subcloned
from pLightSwitch_Prom_UGT1A9 (SwitchGear Genomics, MenloPark, CA, USA) into pGL3-basic (Promega, Wisconsin, MI, USA) at
KpnI and NCoI restriction enzyme sites using the following primers: 50-
GGATTGAGGTACCAACCCC-30 (forward) and 50-AGAGAACTG-
CAGCTGAGAGC-30 (reverse). The resulting plasmid was named as
pGL3-UGT1A9. For deletion assays, 50-deletion constructs were
prepared using pGL3-UGT1A9 (as a template) and a primer set of
the above-mentioned reverse primer and one of the following forward
primers: 50-CGATGGTACCTGGCCTCCCGTGATAC-30 (1987/
þ24), 50-GTGCTGGGACTACAGGTGT-30 (1950/þ24), 50-
CGATGGTACCAGCCTACTGTGCACTAGAAG-30 (1873/þ24),
50-CGATGGTACCAGAGATGTTGGGTTTGCAGG-30 (1182/
þ24), and 50-CGATGGTACCTGAACTCATGGGTTCTGGGT-30
(1133/þ24). Expression vectors for wild-type or mutant ERα were
previously described12. Mutation constructs of pGL3-UGT1A9 cis-
element were prepared using a QuikChange XL Site-Directed Mutagen-
esis Kit (Agilent Technologies, La Jolla, CA, USA) following the
manufacturer's protocol. The following primers were used to make a
mutation construct of pGL3-UGT1A9: 50-GTATGGCGGGAAGCG-
GAGGTTGCATT-30 (forward) and 50-AGTGACCCTCCTGCCT-
CAGCCTCCAGA-30 (reverse). The following primers were used to
make a deletion construct of pGL3-UGT1A9: 50-CGGGAAGCG-
GAGGTTGCATT-30 (forward) and 50-CTCCTGCCTCAGCCTC-
CAGA-30(reverse).
2.4. Human liver tissues
A total of 115 human liver transplant donor tissues without any
gross pathological features were obtained from Corning (Corn-
ing, NY, USA) (n¼50) and Liver Tissues Cell Distribution
Systems (LTCDS; Minneapolis, MN; funded by NIH Contract
HHSN276201200017C) (n¼65). The human tissues from Corn-
ing were obtained with informed consent in accordance with
applicable laws and directly from non-proﬁt organ procurement
operations that have provided assurance as to legal compliance.
Ethical approval for the LTCDS contract was granted by the
University of Minnesota Institutional Review Board (project
1008M87433). Informed written consent was obtained from all
participants involved with LTCDS. Liver tissues were stored at
80 1C until analysis. The tissues were from both males (n¼70,
age¼48716) and females (n¼45, age¼51714); but ethnicity
was unknown.
2.5. RNA isolation and quantitative real-time PCR
Total RNA was isolated from human liver tissues using Trizol
(ThermoFisher Scientiﬁc, Waltham, MA, USA) and converted to
cDNA using High Capacity cDNA Archive Kit (ThermoFisher
Scientiﬁc). Using the cDNA as template, qRT-PCR was performed
using StepOnePlus Real-Time PCR System. PrimeTimes Std
qPCR Assays (Integrated DNA Technologies, Coralville, IA,
USA) were used for CYP3A4 (Hs.PT.58.27726673), UGT1A9
(Hs.PT.58.40314971.g), and HPRT1 (Hs.PT.58.45621572). Rela-
tive mRNA levels of genes were determined after normalizing the
gene expression levels by those of HPRT1 (2ΔΔCt method).
2.6. Luciferase assay
HepG2 or HepG2-ER cells were transfected with 0.7 μg plasmid
(i.e., 0.3 μg luciferase construct, 0.03 μg pcDNA3-ERα, 0.369 μg
pcDNA3, and 0.001 μg pCMV-Renilla for HepG2 cells; 0.3 μg
luciferase construct, 0.399 μg pcDNA3, and 0.001 μg pCMV-
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son, WI, USA). pCMV-Renilla was included to normalize for
differences in transfection efﬁciency. Luciferase activity was
measured by using Dual-Luciferase Reporter Assay System
(Promega). Fireﬂy luciferase activity was normalized by Renilla
luciferase activity. The experiments were performed in triplicate
and repeated at least twice.
2.7. Electrophoretic mobility shift assay (EMSA)
HEK293T cells were transfected with pcDNA3-ERα, and nuclear
extracts were prepared by using CelLytic™ NuCLEAR™ Extrac-
tion Kit (Sigma, St. Louis, MO, USA). EMSA was performed as
previous described10.
2.8. Statistical analysis
All data were presented as mean7standard deviation unless
indicated otherwise. For statistical testing among more than two
groups, one-way analysis of variance test was performed for
multiple comparisons followed by posthoc Dunnett's test using
Prism (Graphpad, San Diego, CA, USA). For testing between two
groups, Student's t-test was performed. Signiﬁcance was set at
Po0.05.3. Results
3.1. E2 induces UGT1A9 expression via ERα
Considering that estrogen exerts its physiological action through
ER, the involvement of ERα (the major subtype in the liver) in
UGT1A9 induction by E2 was investigated by using promoter
reporter assays. HepG2 cells were co-transfected with pGL3-
UGT1A9 (or promoterless pGL3-basic), and ERα expression
vector (or empty vector). The transfected cells were treated with
vehicle or E2 for 24 h, and luciferase activity was measured. The
results showed that E2 signiﬁcantly increased UGT1A9 promoter
activity only in the cells transfected with ERα (Fig. 1A). Such
increase in luciferase activity upon E2 treatment was not observed
for pGL3-basic vector (data not shown). The increase in UGT1A9
promoter activity by E2 in HepG2 cells was dependent on E2Figure 1 E2 induces UGT1A9 expression via ERα. (A) HepG2 cells were
vector) and pCMV-Renilla. The transfected cells were incubated with veh
**Po0.01 vs. lane 1. (B) HepG2 cells were co-transfected with pGL3-UGT
with E2 at different concentrations (0.1, 0.5, 1, 5, 10, 50, 100, 500, or 100
cells were transfected with pGL3-UGT1A9 and pCMV-Renilla. The tran
(10 μmol/L) for 24 h. Then, luciferase assay was performed. ***Po0.001concentration, and EC50 was estimated as 12.4 nmol/L (Fig. 1B).
To verify the involvement of ERα in cells that constitutively
express ERα, HepG2-ER cells were used to examine E2 effects on
UGT1A9 promoter activity. HepG2-ER cells were transfected with
pGL3-UGT1A9, and then treated with E2 (or vehicle) in the
presence or absence of ICI182,780, an ERα antagonist. E2
treatment led to a signiﬁcant increase in UGT1A9 promoter
activity, and this was abolished upon co-treatment with
ICI182,780 (Fig. 1C). Together, these data indicate that E2 up-
regulates UGT1A9 promoter activity via ERα.3.2. Putative ERE is located in 2262/1987 of UGT1A9
To deﬁne the mode of ERα action in enhancing UGT1A9
promoter activity, the effects of ERα mutants on E2 responsive-
ness of UGT1A9 promoter were examined. To this end, HepG2
cells were co-transfected with pGL3-UGT1A9, along with one of
ERα mutants. ERα mutants included in this study have (1) a
deletion of activation function (AF) 1, (2) point mutations in
DNA-binding domain (DBD), (3) point mutations in AF2, or (4) a
combination of the mutations. The transfected HepG2 cells were
treated with E2, and luciferase activity was measured. The results
showed that all of the ERα mutants decreased E2 response of
pGL3-UGT1A9 (Fig. 2A), a phenomenon previously observed for
pGL3-ERE3 where luc expression is driven by 3 copies of
consensus ERE12. Importantly, E2 response was abrogated upon
mutation at DBD, indicating that direct binding of ERα to its target
gene promoter is critical in UGT1A9 induction by E2.
To identify cis-element(s) responsible for the enhanced UGT1A9
promoter activity by E2, deletion assays were performed. To this end,
a set of luciferase vector containing different 50-upstream regulatory
region of UGT1A9 (2262/þ24, 1987/þ24, 1950/þ24,
1873/þ24, 1182/þ24 and 1133/þ24) was constructed.
HepG2 cells were transfected with one of the luciferase vectors,
along with ERα expression vector, followed by E2 (or vehicle)
treatment. The result showed that E2 response of UGT1A9 promoter
was abolished when 2262/1987 region was deleted (Fig. 2B).
The 2262/1987 of UGT1A9 was found to harbor a putative ERE
(Fig. 2C). To further examine the role of putative ERE, luciferase
vectors harboring deleted or mutated ERE of UGT1A9 were
constructed. The luciferase vector was co-transfected into HepG2
cells along with ERα, followed by E2 treatment. Dramatic decreasesco-transfected with pGL3-UGT1A9, ERα expression vector (or empty
icle or E2 (100 nmol/L) for 24 h, and luciferase assay was performed.
1A9, ERα expression vector and pCMV-Renilla, followed by treatment
0 nmol/L). After 24 h, luciferase assay was performed. (C) HepG2-ER
sfected cells were treated with E2 (100 nmol/L) and/or ICI182,780
vs. lane 1.
Figure 2 Putative ERE is located in 2262/1987 of UGT1A9. (A) HepG2 cells were co-transfected with pGL3-UGT1A9, an ERα mutant
vector and pCMV-Renilla. The cells were treated with vehicle or E2 (100 nmol/L) for 24 h, and luciferase assay was performed. Black box denotes
the presence of multiple point mutations in ERα domain. (B) HepG2 cells were transfected with a 50-deletion construct of pGL3-UGT1A9, ERα
expression vector, and pCMV-Renilla. The cells were treated with vehicle or E2 (100 nmol/L) for 24 h, and luciferase assay was performed.
(C) Putative ERE (boxed) and half ERE (underlined) within –2262/–1987 of UGT1A9 (identiﬁed by using ERα matrix22) are shown. (D) HepG2
cells were co-transfected with UGT1A9 promoter vector harboring wild-type, mutated (black box), or deleted putative ERE, along with ERα
expression vector and pCMV-Renilla. In the mutation or deletion construct, the putative ERE sequence was muted to 50-CCATACAGTGACC-30
or deleted, respectively. The transfected cells were incubated with vehicle or E2 (100 nmol/L) for 24 h, and luciferase assay was performed.
Figure 3 ERα does not bind to UGT1A9 probe. Nuclear proteins
were prepared from HEK239T cells transfected with ERα expression
vector. The proteins were incubated with 32P-labeled DNA probe
harboring either the consensus ERE or the putative ERE of UGT1A9,
in the presence or absence of ERα antibody. The mixture was resolved
on non-denaturing gel. The lower arrow indicates the location of
shifted bands by ERα binding to ERE. The upper arrow indicates a
super-shift complex.
UGT1A9 induction by E2 507in E2 response were observed when the putative ERE was mutated or
deleted (Fig. 2D). These results suggest a key role of the putative ERE
in UGT1A9 upregulation by E2.
To determine whether ERα directly binds to the putative ERE
of UGT1A9, electrophoretic mobility assays (EMSA) was per-
formed. Short double-stranded DNA probe harboring UGT1A9
putative ERE (the sequence of which is shown in Fig. 3) was
incubated with nuclear extracts prepared from HEK293T cells that
overexpress ERα. Protein-bound probes were separated from free
probes using gel electrophoresis. A DNA probe harboring the
previously known consensus ERE sequence was included as a
positive control. The consensus ERE probe exhibited a shifted
band (Fig. 3, lane 2) that was super-shifted by ERα antibody
(Fig. 3, lane 3); however, the UGT1A9 probe did not show any
prominent shifted or super-shifted bands (Fig. 3, lane 5 and 6),
indicating that ERα did not bind to the UGT1A9 probe.
3.3. mRNA expression of UGT1A9 was higher in women than
men in human liver tissues
To verify the role of estrogen in the regulation of UGT1A9
expression, sex difference in UGT1A9 expression was examined
in human liver tissues. In healthy human liver tissues (n¼115),
mRNA expression levels of UGT1A9 expression were compared
between males (n¼70, age¼48716) and females (n¼45,
age¼51714). CYP3A4, a gene known to exhibit sex difference
in its expression13, was included as a positive control. Statistically
signiﬁcant sex difference was detected in both UGT1A9 and
CYP3A4 expression (Fig. 4).4. Discussion
In this study, using transient transfection and promoter reporter
assays, we showed that E2 upregulates UGT1A9 expression via
ERα in HepG2 and HepG2-ER cells. Our results are in agreementwith previous clinical data that showed increased glucuronidation
of UGT1A9 substrates (i.e., propofol and acetaminophen) in
women (than in men) or oral contraceptive users (than in non-
users)7–9. To further verify our ﬁndings in HepG2 cells in a more
physiologically relevant system, we treated primary human hepa-
tocytes with E2 and examined UGT1A9 expression. The results
Figure 4 Relative mRNA expression levels of CYP3A4 and UGT1A9 are higher in women than in men. mRNA expression of CYP3A4 and
UGT1A9 in the human liver tissues (n¼115) were measured by qRT-PCR, and normalized by the levels in an arbitrarily chosen liver tissue. The
red and error bars represent the mean and standard error, respectively. *Po0.05; ****Po0.0001.
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between E2- and vehicle-treated hepatocytes (data not shown),
in part consistent with a previous report of relatively poor
inducibility of UGTs in primary hepatocytes14. This likely
indicates a limitation of human hepatocytes as a model to study
regulation of UGT expression. Together, our data provide
mechanistic support for the clinical ﬁndings of UGT-mediated
metabolism and suggest important roles of estrogen in determining
UGT1A9 expression and activity.
The mode of ERα action in UGT1A9 upregulation appears
complex. Results from deletion and mutation assays revealed that
the putative ERE within 2262/1987 of UGT1A9 plays a key role
in promoter activation by E2. Also, studies using ERα mutants
revealed that ERα enhances UGT1A9 promoter activity via direct
DNA binding. Interestingly, however, the results from EMSA
showed that ERα did not directly bind to a DNA probe harboring
the putative ERE of UGT1A9. This may reﬂect weak interaction
between the DNA and ERα, and the need for binding of additional
transcription factor(s) to the regulatory region of UGT1A9. It has
been reported that imperfect EREs or half EREs that are located in the
proximity of each other signiﬁcantly enhance ERα binding to the
DNA15,16. Three half-EREs are found at 9-, 20- and 27-bp away from
the putative ERE of UGT1A9, and it appears possible that these half-
EREs enhance the ERα binding to the regulatory region of UGT1A9.
UGT1A9-mediated drug metabolism in humans exhibits large
inter-individual variability17–19. We also found that UGT1A9
expression exhibited 4300-fold difference in our human liver
tissues. Several factors are known to alter UGT1A9 expression,
including genetic polymorphisms of UGT1A9 and differential
expression levels of transcriptional factors20,21. Our results indi-
cating the regulatory role of estrogen in UGT1A9 expression
suggest sex as an additional potential contributor to UGT1A9
variability. Indeed, UGT1A9 expression in human liver tissues
was found to be higher in women than in men, similarly to
CYP3A4, in our study. Notably, although the ethnicity of the
donors and circulating estrogen levels are not known for the tissue
samples analyzed, our ﬁnding is consistent with the proposed
regulatory role of estrogen. The extent of contribution by sex to
UGT1A9 variability, as compared to that by other known factors
that alter UGT1A9 expression, remains to be determined.
In conclusion, we demonstrated that E2 up-regulates UGT1A9
expression via ERα. This provides mechanistic insights into
previously reported increases in UGT1A9-mediated drug metabo-
lism in pregnant women or oral contraceptive users. This ﬁndingmay also shed a light on identifying sources for inter-individual
variability in UGT1A9-mediated drug metabolism.
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